| IDASANUTLIN | Small molecule | diffuse large B-cell lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| TEPRASIRAN | Oligonucleotide | Acute kidney injury | p53 mRNA RNAi inhibitor | 2.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | essential thrombocythemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 3.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | breast cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | melanoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | multiple myeloma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | small cell lung carcinoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| TEPRASIRAN | Oligonucleotide | Acute kidney injury | p53 mRNA RNAi inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | multiple myeloma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | non-Hodgkins lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| EPRENETAPOPT | Small molecule | esophageal carcinoma | Cellular tumor antigen p53 stabiliser | 1.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | essential thrombocythemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| APG115 | Small molecule | lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | colorectal carcinoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | soft tissue sarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| EPRENETAPOPT | Small molecule | myeloid neoplasm | Cellular tumor antigen p53 stabiliser | 1.0 | Completed | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | liver cancer | Cellular tumor antigen p53 positive modulator | 1.0 | Terminated | ClinicalTrials |
| APG115 | Small molecule | myelodysplastic syndrome | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | Uveal Melanoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| EPRENETAPOPT | Small molecule | Mantle cell lymphoma | Cellular tumor antigen p53 stabiliser | 2.0 | Withdrawn | ClinicalTrials |
| EPRENETAPOPT | Small molecule | melanoma | Cellular tumor antigen p53 stabiliser | 1.0 | Terminated | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | lung cancer | Cellular tumor antigen p53 positive modulator | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | breast cancer | Cellular tumor antigen p53 positive modulator | 1.0 | Completed | ClinicalTrials |
| SIREMADLIN | Small molecule | myelofibrosis | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| APG115 | Small molecule | chronic myelomonocytic leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | myelofibrosis | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| APG115 | Small molecule | lymphoid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| APG115 | Small molecule | liposarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| EPRENETAPOPT | Small molecule | ovarian cancer | Cellular tumor antigen p53 stabiliser | 2.0 | Completed | ClinicalTrials |
| SIREMADLIN | Small molecule | soft tissue sarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | glioblastoma multiforme | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | ovarian cancer | Cellular tumor antigen p53 positive modulator | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Suspended | ClinicalTrials |
| EPRENETAPOPT | Small molecule | myelodysplastic syndrome | Cellular tumor antigen p53 stabiliser | 3.0 | Completed | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| APG115 | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | urinary bladder carcinoma | Cellular tumor antigen p53 positive modulator | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | myeloproliferative disorder | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | Merkel cell skin cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| CENERSEN | Oligonucleotide | acute myeloid leukemia | p53 mRNA antisense inhibitor | 2.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | chronic myelogenous leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| CENERSEN SODIUM | Oligonucleotide | chronic lymphocytic leukemia | p53 mRNA antisense inhibitor | 2.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | plasmacytoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | follicular lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | breast cancer | Cellular tumor antigen p53 positive modulator | 2.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | gliosarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Suspended | ClinicalTrials |
| SIREMADLIN | Small molecule | liposarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIREMADLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | primary myelofibrosis | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CENERSEN | Oligonucleotide | acute myeloid leukemia | p53 mRNA antisense inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | non-small cell lung carcinoma | Cellular tumor antigen p53 positive modulator | 2.0 | Unknown status | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | head and neck malignant neoplasia | Cellular tumor antigen p53 positive modulator | 2.0 | Unknown status | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | Central Nervous System Neoplasm | Cellular tumor antigen p53 positive modulator | 1.0 | Completed | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | neoplasm | Cellular tumor antigen p53 positive modulator | 4.0 | Unknown status | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | peritoneum cancer | Cellular tumor antigen p53 positive modulator | 1.0 | Completed | ClinicalTrials |
| APG115 | Small molecule | salivary gland cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | liver disease | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| CONTUSUGENE LADENOVEC | Gene | head and neck malignant neoplasia | Cellular tumor antigen p53 positive modulator | 2.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| EPRENETAPOPT | Small molecule | ovarian cancer | Cellular tumor antigen p53 stabiliser | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| CENERSEN | Oligonucleotide | myelodysplastic syndrome | p53 mRNA antisense inhibitor | 1.0 | Terminated | ClinicalTrials |